Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 23, 2019
Reporting Period: Single event date (September 23, 2019)
Business Context: The Company is an emerging growth company incorporated in Nevada, trading on NASDAQ under the symbol "INMB". This filing serves as a Regulation FD disclosure regarding a scheduled presentation at a medical conference.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces a future corporate activity.
Guidance, Outlook, and Management Commentary
- Upcoming Event: The Company announced it will present at the Alzheimer's Association International Conference (AAIC) Satellite Symposium.
- Event Details: The symposium is scheduled for September 25–27, 2019, in Sydney, Australia.
- Disclosure Status: The press release detailing this event is furnished as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the content of the press release furnished as Exhibit 99.1 for specific details on the presentation topic.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.